• Immuron exceeds AUD$5 million in sales in a fiscal year, highest sales in history
• March 2025 Quarter AUD$1.3 million up 2% on prior year
• March 2025 Year to Date AUD$5.3 million up 46% on prior year

Immuron Limited, an Australian based and globally integrated biopharmaceutical company, is pleased to announce continued sales growth (unaudited) of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract. For the first time, Immuron has exceeded A$5 million in sales - its highest fiscal year sales ever, with a quarter still to come. This is a fantastic result, with record sales in the March 2025 Quarter of AUD$1.3 million, up 2% on the prior year. The March 2025 Year to Date sales globally is up 46% on last year, reaching AUD$5.3 million. In Australia, the March 2025 Year to Date sales reached AUD$3.7 million, up 34% on the prior year, while in North America, the March 2025 Year to Date sales reached AUD$1.6 million, up 86% on the prior year. The company continues to strengthen its consumer and trade program, which has seen Travelan® ranked #1 by market share change, #2 by SKU and #3 by brand in the Anti-diarrheal category in Australia. The company is on track for another record year in Australia and has achieved record sales in both the USA and Canada.

With strong sales anticipated over the Easter, ANZAC holiday periods and spring, summer break in North America, the company has great momentum to build further on this record-breaking year.